New cancer clinical trial: the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment

Published on: November 30, 2017 at 10:00AM
Condition:   Triple Negative Breast Cancer
Interventions:   Drug: Vinorelbine Tartrate;   Drug: Capecitabine 500 MG
Sponsor:   Mario Negri Institute for Pharmacological Research
Recruiting
http://ift.tt/2zRrSBh